Who
Rachel McMinn
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Neurogene; Chief Strategy Officer, Intercept Pharmaceuticals.
In numbers
- Trades disclosed
- 37
- Buys
- 1
- Sells
- 17
- Bought
- $969K
- Sold
- $689K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 30 Apr 2014
- Last trade
- 22 Sep 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Sep 2026filed 2 Oct 2026 | NGNE NeurogeneBiotechnology | SEC FORM 4 Code M | $19K756 at $25.32 | filing |
| 22 Sep 2026filed 2 Oct 2026 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code M | —756 at $0.00 | filing |
| 26 Mar 2026filed 30 Mar 2026 | NGNE NeurogeneBiotechnology | SEC FORM 4 Sold | $74K3,352 at $22.07 | filing |
| 26 Mar 2026filed 30 Mar 2026 | NGNE NeurogeneBiotechnology | SEC FORM 4 Sold | $74K3,352 at $22.07 | filing |
| 20 Feb 2026filed 24 Feb 2026 | NGNE NeurogeneBiotechnology | SEC FORM 4 Code A | —25,900 at $0.00 | filing |
| 20 Feb 2026filed 24 Feb 2026 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —155,100 at $0.00 | filing |
| 20 Feb 2026filed 24 Feb 2026 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —155,100 at $0.00 | filing |
| 20 Feb 2026filed 24 Feb 2026 | NGNE NeurogeneBiotechnology | SEC FORM 4 Code A | —25,900 at $0.00 | filing |
| 26 Mar 2025filed 28 Mar 2025 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —143,500 at $0.00 | filing |
| 26 Mar 2025filed 28 Mar 2025 | NGNE NeurogeneBiotechnology | SEC FORM 4 Code A | —23,900 at $0.00 | filing |
| 22 Nov 2024filed 25 Nov 2024 | NGNE NeurogeneBiotechnology | SEC FORM 4 Bought | $969K47,500 at $20.40 | filing |
| 13 Mar 2024filed 14 Mar 2024 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —93,282 at $0.00 | filing |
| 2 Oct 2017filed 4 Oct 2017 | Intercept Pharmaceuticals | SEC FORM 4 Sold | $17K283 at $58.89 | filing |
| 31 Jul 2017filed 2 Aug 2017 | Intercept Pharmaceuticals | SEC FORM 4 Sold | $16K130 at $123.12 | filing |
| 3 Jul 2017filed 5 Jul 2017 | Intercept Pharmaceuticals | SEC FORM 4 Sold | $31K257 at $121.78 | filing |
| 1 May 2017filed 3 May 2017 | Intercept Pharmaceuticals | SEC FORM 4 Sold | $13K114 at $113.12 | filing |
| 3 Apr 2017filed 5 Apr 2017 | Intercept Pharmaceuticals | SEC FORM 4 Sold | $30K257 at $115.00 | filing |
| 1 Feb 2017filed 3 Feb 2017 | Intercept Pharmaceuticals | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 1 Feb 2017filed 3 Feb 2017 | Intercept Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —8,300 at $0.00 | filing |
| 3 Jan 2017filed 5 Jan 2017 | Intercept Pharmaceuticals | SEC FORM 4 Sold | $85K816 at $103.92 | filing |
News
Neurogene Inc.: Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual CongressNGNE · finanznachrichten.de · 20 Oct 2026
0 headlines in the last 90 days name Rachel McMinn; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.